Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schuh Anna, Ayvaz Goksun, Baldeschi Lelio, Baretić Maja, Bechtold Dorte, Boschi Antonella, Brix Thomas Heiberg, Burlacu Maria-Cristina, Ciric Jasmina, Covelli Danila, Currò Nicola, Donati Simone, Eckstein Anja K, Fichter Nicole, Führer Dagmar, Horn Maren, Jabłońska-Pawlak Anna, Juri Mandić Jelena, Kahaly George J, Konuk Onur, Langbein Amelie, Lanzolla Giulia, Marcocci Claudio, Marinò Michele, Miśkiewicz Piotr, Beleslin Biljana Nedeljkovic, Pérez-Lázaro Antonia, Pérez-López Marta, Ponto Katharina A, Quinn Anthony, Rudofsky Gottfried, Salvi Mario, Schittkowski Michael P, Tanda Maria Laura, Toruner Fusun, Vaidya Bijay, Hintschich Christoph R
Аннотация
METHODS: Prospective observational multicentre study. All new referrals with diagnosis of GO within September-December 2019 were included. Clinical and demographic characteristics, referral timelines and initial therapeutic decisions were recorded. Data were compared with a similar EUGOGO survey performed in 2012.
RESULTS: Besides age (mean age: 50.5±13 years vs 47.7±14 years; p 0.007), demographic characteristics of 432 patients studied in 2019 were similar to those in 2012. In 2019, there was a decrease of severe cases (9.8% vs 14.9; p<0.001), but no significant change in proportion of active cases (41.3% vs 36.6%; p 0.217). After first diagnosis of GO, median referral time to an EUGOGO tertiary centre was shorter (2 (0-350) vs 6 (0-552) months; p<0.001) in 2019. At the time of first visit, more patients were already on antithyroid medications (80.2% vs 45.0%; p<0.001) or selenium (22.3% vs 3.0%; p<0.001). In 2019, the initial management plans for GO were similar to 2012, except for lid surgery (2.4% vs 13.9%; p<0.001) and prescription of selenium (28.5% vs 21.0%; p 0.027).
CONCLUSION: GO patients are referred to tertiary EUGOGO centres in a less severe stage of the disease than before. We speculate that this might be linked to a broader awareness of the disease and faster and adequate delivered treatment.